Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
XENE Xenon Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: XENE
Price (delayed)
$30.29
Market cap
$2.32B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.23
Enterprise value
$2.22B
Xenon is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. The Company is advancing a novel product pipeline of
Highlights
XENE's debt is down by 17% year-on-year and by 3.8% since the previous quarter
The quick ratio has contracted by 45% YoY
The net income has declined by 33% year-on-year and by 7% since the previous quarter
Key stats
What are the main financial stats of XENE
Market
Valuations
Earnings
Shares outstanding
76.73M
Market cap
$2.32B
Enterprise value
$2.22B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.29
Price to sales (P/S)
317.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
295.5
Revenue
$7.5M
Gross profit
$7.5M
Operating income
-$293M
Net income
-$251.45M
EBIT
-$255.52M
EBITDA
-$251.32M
Free cash flow
-$202.79M
Per share
Balance sheet
Liquidity
EPS
-$3.23
EPS diluted
-$3.23
Free cash flow per share
-$2.58
Book value per share
$9.2
Revenue per share
$0.1
TBVPS
$9.45
Total assets
$743.28M
Total liabilities
$39.32M
Debt
$8.68M
Equity
$703.96M
Working capital
$533.51M
Debt to equity
0.01
Current ratio
17.66
Quick ratio
17.43
Net debt/EBITDA
0.43
Margins
Efficiency
Dividend
EBITDA margin
-3,351%
Gross margin
100%
Net margin
-3,352.6%
Operating margin
-3,906.6%
Return on assets
-30.8%
Return on equity
-32.4%
Return on invested capital
-38%
Return on capital employed
-35.9%
Return on sales
-3,406.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XENE stock price
How has the Xenon Pharmaceuticals stock price performed over time
Intraday
2.43%
1 week
-13.51%
1 month
-10.33%
1 year
-24.91%
YTD
-22.73%
QTD
-9.72%
Financial performance
How have Xenon Pharmaceuticals's revenue and profit performed over time
Revenue
$7.5M
Gross profit
$7.5M
Operating income
-$293M
Net income
-$251.45M
Gross margin
100%
Net margin
-3,352.6%
The net income has declined by 33% year-on-year and by 7% since the previous quarter
The operating income is down by 31% year-on-year and by 4.9% since the previous quarter
Price vs fundamentals
How does XENE's price correlate with its fundamentals
Growth
What is Xenon Pharmaceuticals's growth rate over time
Valuation
What is Xenon Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.29
P/S
317.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
295.5
The EPS fell by 19% YoY and by 7% QoQ
The company's equity fell by 21% YoY and by 7% QoQ
XENE's price to book (P/B) is 11% lower than its last 4 quarters average of 3.7 but 6% higher than its 5-year quarterly average of 3.1
Efficiency
How efficient is Xenon Pharmaceuticals business performance
XENE's return on invested capital is down by 41% year-on-year and by 17% since the previous quarter
Xenon Pharmaceuticals's return on equity has decreased by 33% YoY and by 14% QoQ
Xenon Pharmaceuticals's return on assets has decreased by 32% YoY and by 13% QoQ
Dividends
What is XENE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XENE.
Financial health
How did Xenon Pharmaceuticals financials performed over time
XENE's current ratio is down by 45% year-on-year
The quick ratio has contracted by 45% YoY
XENE's debt is 99% smaller than its equity
The company's equity fell by 21% YoY and by 7% QoQ
XENE's debt is down by 17% year-on-year and by 3.8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.